Symptom Monitoring in Hemodialysis

Launched by UNIVERSITY OF PENNSYLVANIA · Feb 10, 2023

Keywords

ClinConnect Summary

The SMaRRT-HD trial is studying how monitoring symptoms in patients receiving hemodialysis can improve their care and well-being. This trial involves about 2,400 patients from 30 different hemodialysis clinics across the United States. Some clinics will use a new system called SMaRRT-HD, which allows patients to report their symptoms using a tablet. This system also helps doctors follow up on those symptoms to ensure patients receive the right treatment and support. The goal is to reduce suffering and enhance communication between patients and their healthcare teams. Other clinics will continue with the usual care, which means monitoring symptoms during regular appointments.

To join the study, participants must be at least 18 years old, speak English or Spanish, and be receiving hemodialysis at a participating clinic. It's important that they are willing to report their symptoms through the SMaRRT-HD system and share their health information with the research team. Participants in the SMaRRT-HD group can expect to use a user-friendly tablet to share their symptoms regularly, and receive timely support from their healthcare providers. This trial aims to make a real difference in how patients experience their treatment and manage their symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Treatment with hemodialysis at a participating dialysis clinic
• • English or Spanish speaking
• Exclusion Criteria:
• • Not willing to report their symptoms using the SMaRRT-HD platform
• • Not willing to share clinically acquired data with the research team
• • Underlying condition such as dementia that is anticipated to prevent comprehension of the trial information document (fact sheet)
• • Incarceration